TY - JOUR
T1 - Continuous downstream processing
AU - Jungbauer, Alois
AU - Satzer, Peter
AU - Duerauer, Astrid
AU - Azevedo, Ana
AU - Aires-Barros, Raquel
AU - Nilsson, Bernt
AU - Farid, Suzy
AU - Goldrick, Stephen
AU - Ottens, Marcel
AU - More Authors, null
PY - 2024/6/19
Y1 - 2024/6/19
N2 - The main objectives of bioprocesses are to reliably deliver drugs in a relatively short time frame with high quality within a tight regulatory framework. Bioprocesses are highly complex, the level of automation is moderate, and there is constant pressure to improve efficiency and costs. In addition, climate change and resource scarcity mandate a reduction in the environmental footprint of bioprocesses and production facilities. In the biopharmaceutical industry, two extreme production scenarios are applied: a fully disposable factory with the characteristics of full flexibility and speed, or a fixed large-scale plant with high capacity. Forward-looking solutions and ideas will be discussed how to combine new processes and environmental friendliness for the benefit of the patient, security of supply and profitability. The concept will be extended to large scale production of proteins for food and non-pharma applications, e.g., in material science and a roadmap towards a future plant will be laid out.
AB - The main objectives of bioprocesses are to reliably deliver drugs in a relatively short time frame with high quality within a tight regulatory framework. Bioprocesses are highly complex, the level of automation is moderate, and there is constant pressure to improve efficiency and costs. In addition, climate change and resource scarcity mandate a reduction in the environmental footprint of bioprocesses and production facilities. In the biopharmaceutical industry, two extreme production scenarios are applied: a fully disposable factory with the characteristics of full flexibility and speed, or a fixed large-scale plant with high capacity. Forward-looking solutions and ideas will be discussed how to combine new processes and environmental friendliness for the benefit of the patient, security of supply and profitability. The concept will be extended to large scale production of proteins for food and non-pharma applications, e.g., in material science and a roadmap towards a future plant will be laid out.
KW - Continuous integrated biomanufacturing
KW - Economics
KW - Environmental footprint
KW - Microfluidics
KW - Scale down
UR - http://www.scopus.com/inward/record.url?scp=85184072929&partnerID=8YFLogxK
U2 - 10.1016/j.seppur.2024.126439
DO - 10.1016/j.seppur.2024.126439
M3 - Review article
AN - SCOPUS:85184072929
SN - 1383-5866
VL - 338
JO - Separation and Purification Technology
JF - Separation and Purification Technology
M1 - 126439
ER -